BioSpace News Archive

bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies.

XVIVO is setting new standards in heart transplantation. In an ongoing clinical trial in Australia and New Zealand, a donor heart was preserved using Non Ischemic Heart Preservation technology for 7 hours and 18 minutes before successful transplantation into a 55-year-old man.

SPR Therapeutics announced today it has raised $37 million in an oversubscribed Series D growth equity financing.

The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical trials evaluating its CC-96191 and CC-92328 NK cell engager therapies in patients with hematologic malignancies.

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease

BioMark is proud to participate in this premiere event that aims to address the principal advances in the world of the liquid biopsy.

Matica Biotechnology, Inc today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry.

Phase Genomics leverages its proprietary ultra-long-range sequencing technology in release of new RUO platform: the first high-resolution, low-cost solution to detect chromosome abnormalities

AB SCIENCE GRANTED AUTHORIZATION FROM THE FRENCH HEALTH AUTHORITY (ANSM) TO INITIATE A STUDY OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

Angion Biomedica Corp today announced it will be presenting four posters at the American Society of Nephrology’s Kidney Week 2021 virtual meeting to be held November 4-7, 2021.